-
公开(公告)号：US10392347B2
公开(公告)日：2019-08-27
申请号：US15767364
申请日：2016-10-13
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Soong-Hoon Kim , Hannguang J. Chao , Heather Finlay , Ji Jiang , James A. Johnson , R. Michael Lawrence , Michael C. Myers , Monique Phillips , George O. Tora , Wei Meng
IPC: C07D213/82 , C07D401/06 , C07D401/14 , C07D405/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D491/107 , C07D498/10 , C07D401/12 , C07D471/10
Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.
-
公开(公告)号：US20190233449A1
公开(公告)日：2019-08-01
申请号：US16318173
申请日：2017-07-21
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Peter T.W. CHENG , Wei Meng , Mark Liu , Bei Wang , Rulin Zhao
IPC: C07F9/6571 , A61P3/10
CPC classification number: C07F9/657181 , A61P3/10 , C07B2200/13
Abstract: A compound, enantiomer, prodrug, diastereomer, or salt is provided which is an activator of the enzyme glucokinase and thus is believed to be useful in as treating diabetes and related diseases, which compound has the structure (I). A method for treating diabetes and related disease employing the compound, enantiomer, prodrug, diastereomer, or salt is also provided.
-
公开(公告)号：US20180297954A1
公开(公告)日：2018-10-18
申请号：US15767364
申请日：2016-10-13
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Soong-Hoon Kim , Hannguang J. Chao , Heather Finlay , Ji Jang , James A. Johnson , R. Michael Lawrence , Michael C. Myers , Monique Phillips , George O. Tora , Wei Meng
IPC: C07D213/82 , C07D401/12 , C07D401/14 , C07D413/14 , C07D401/06 , C07D405/14 , C07D417/14 , C07D417/12 , C07D498/10 , C07D413/12 , C07D491/107 , C07D471/10
CPC classification number: C07D213/82 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/10 , C07D491/107 , C07D498/10
Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, O and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.
-
公开(公告)号：US09901572B2
公开(公告)日：2018-02-27
申请号：US15488642
申请日：2017-04-17
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Huji Turdi , Jon J. Hangeland , R. Michael Lawrence , Saleem Ahmad , Wei Meng , Robert Paul Brigance , Pratik Devasthale , Guohua Zhao
IPC: C07D211/90 , C07D401/04 , A61K31/4439 , A61K31/438 , A61K31/675 , A61K31/4418 , C07D413/04 , C07D221/20 , C07D413/14 , A61K31/5377 , C07F9/59 , C07D401/14 , A61K45/06 , C07D401/10 , C07D401/12 , C07D407/14 , C07D413/12 , C07D417/04 , C07D417/14 , C07D211/86 , C07F9/535 , C07F9/40 , C07D405/14
CPC classification number: A61K31/438 , A61K31/4418 , A61K31/4439 , A61K31/5377 , A61K31/675 , A61K45/06 , C07D211/86 , C07D211/90 , C07D221/20 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/14 , C07D407/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/14 , C07F9/4006 , C07F9/5352 , C07F9/59
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
-
公开(公告)号：US20170267666A1
公开(公告)日：2017-09-21
申请号：US15617079
申请日：2017-06-08
Applicant: Bristol-Myers Squibb Company
Inventor： Wei Meng , Guohua Zhao
IPC: C07D409/14 , C07D401/04 , C07D409/04 , C07D417/14 , A61K31/506 , A61K31/444 , A61K31/4439 , A61K31/4436 , C07D401/14 , A61K45/06
CPC classification number: C07D409/14 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K31/506 , A61K45/06 , C07D401/04 , C07D401/14 , C07D409/04 , C07D417/14
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
-
Patent Agency Ranking
公开(公告)号：US10590113B2
公开(公告)日：2020-03-17
申请号：US16122975
申请日：2018-09-06
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Zulan Pi , Donna M. Bilder , Robert Paul Brigance , Heather Finlay , Wen Jiang , James A. Johnson , R. Michael Lawrence , Wei Meng , Michael C. Myers , Monique Phillips , George O. Tora , Xiaojun Zhang
IPC: A61K31/505 , C07D403/06 , C07D401/06 , C07D403/14 , C07D239/557 , C07D239/54 , C07D239/545 , C07D401/14 , C07D403/02 , C07D417/14 , C07D471/04
Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.
-
公开(公告)号：US20190314346A1
公开(公告)日：2019-10-17
申请号：US16445913
申请日：2019-06-19
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Huji Turdi , Jon J. Hangeland , R. Michael Lawrence , Saleem Ahmad , Wei Meng , Robert Paul Brigance , Pratik Devasthale , Guohua Zhao
IPC: A61K31/438 , C07F9/59 , C07D401/10 , C07D401/14 , A61K31/5377 , C07D413/14 , C07D221/20 , C07D413/04 , A61K31/4439 , C07D401/04 , A61K31/4418 , C07D211/90 , A61K31/675 , C07D405/14 , C07F9/40 , C07F9/535 , C07D211/86 , C07D417/14 , C07D417/04 , C07D413/12 , C07D407/14 , C07D401/12 , A61K45/06
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
-
公开(公告)号：US20180133198A1
公开(公告)日：2018-05-17
申请号：US15867825
申请日：2018-01-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Huji Turdi , Jon J. Hangeland , R. Michael Lawrence , Saleem Ahmad , Wei Meng , Robert Paul Brigance , Pratik Devasthale , Guohua Zhao
IPC: A61K31/438 , C07F9/59 , A61K31/4418 , C07F9/40 , C07D417/14 , C07D417/04 , C07D413/14 , C07D413/12 , C07D413/04 , C07D407/14 , C07D405/14 , C07D401/14 , C07D401/12 , C07D401/10 , C07D401/04 , C07D221/20 , C07D211/90 , C07D211/86 , A61K45/06 , A61K31/675 , A61K31/5377 , A61K31/4439 , C07F9/535
CPC classification number: A61K31/438 , A61K31/4418 , A61K31/4439 , A61K31/5377 , A61K31/675 , A61K45/06 , C07D211/86 , C07D211/90 , C07D221/20 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/14 , C07D407/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/14 , C07F9/4006 , C07F9/5352 , C07F9/59
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
-
公开(公告)号：US20160031816A1
公开(公告)日：2016-02-04
申请号：US14883067
申请日：2015-10-14
Applicant: Bristol-Myers Squibb Company
Inventor： Huji Turdi , Jon J. Hangeland , R. Michael Lawrence , Dong Cheng , Saleem Ahmad , Wei Meng , Robert Paul Brigance , Pratik Devasthale , Guohua Zhao
IPC: C07D211/90 , C07D221/20 , C07D401/10 , C07D401/04 , C07D405/14 , C07D401/14 , C07D211/86 , C07D417/04 , C07D413/12 , C07D401/12 , C07D413/04
CPC classification number: A61K31/438 , A61K31/4418 , A61K31/4439 , A61K31/5377 , A61K31/675 , A61K45/06 , C07D211/86 , C07D211/90 , C07D221/20 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/14 , C07D407/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/14 , C07F9/4006 , C07F9/5352 , C07F9/59
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
-
公开(公告)号：US08791091B2
公开(公告)日：2014-07-29
申请号：US13688584
申请日：2012-11-29
Applicant: Bristol-Myers Squibb Company
Inventor： Huji Turdi , Jon J. Hangeland , R. Michael Lawrence , Saleem Ahmad , Wei Meng , Robert Paul Brigance , Pratik Devasthale , Guohua Zhao
IPC: A61K31/675 , A61K31/4418 , A61K45/06 , A61K31/438 , A61K31/4439 , A61K31/5377 , C07D401/04 , C07D413/04 , C07D413/14 , C07F9/59 , C07D401/14 , C07D211/90 , C07D221/20
CPC classification number: A61K31/438 , A61K31/4418 , A61K31/4439 , A61K31/5377 , A61K31/675 , A61K45/06 , C07D211/86 , C07D211/90 , C07D221/20 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/14 , C07D407/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/14 , C07F9/4006 , C07F9/5352 , C07F9/59
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
Abstract translation: 本发明提供式（I）化合物或其立体异构体或其药学上可接受的盐，其中所有变量如本文所定义。 这些化合物是可用作药物的单酰基甘油酰基转移酶2型（MGAT2）抑制剂。
-
-
-
-
-
-
-
-
-
Search Results
40
records
(took 0.045 seconds)
